Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-02-05 00:00:00 ET · period of report 2026-02-04 · accession 0001943192-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-05 | 2026-02-04 | TVTX | Cline Christopher R. | CFO | S - Sale | $32.19 | -1,745 | 111.3K | -2% | -$56.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-04 | S | D | 110 | $32.90 | 111,226 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-04 | S | D | 1,635 | $32.14 | 111,336 | D | — | — | (F2) The weighted average sale price for the transaction reported was $32.14, and the range of prices were between $31.645 and $32.645. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |